Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC, Edelman SV, Konrad RJ, Ortmann RA, Pollom RK, Huster WJ, Zielonka JS, Prince MJ. Ilag LL, et al. Among authors: prince mj. Diabetes Obes Metab. 2016 Feb;18(2):159-68. doi: 10.1111/dom.12584. Epub 2016 Jan 8. Diabetes Obes Metab. 2016. PMID: 26434665 Free PMC article. Clinical Trial.
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Rosenstock J, et al. Among authors: prince mj. Diabetes Care. 2013 Mar;36(3):522-8. doi: 10.2337/dc12-0067. Epub 2012 Nov 27. Diabetes Care. 2013. PMID: 23193209 Free PMC article. Clinical Trial.
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, Huster WJ, Prince MJ. Rosenstock J, et al. Among authors: prince mj. Diabetes Obes Metab. 2015 Aug;17(8):734-41. doi: 10.1111/dom.12482. Epub 2015 May 31. Diabetes Obes Metab. 2015. PMID: 25931141 Clinical Trial.
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC, Dahl D, Rosenstock J, Ilag LL, Huster WJ, Zielonka JS, Pollom RK, Prince MJ. Blevins TC, et al. Among authors: prince mj. Diabetes Obes Metab. 2015 Aug;17(8):726-33. doi: 10.1111/dom.12496. Epub 2015 Jun 23. Diabetes Obes Metab. 2015. PMID: 25974640 Clinical Trial.
Appraising the mitogenicity of insulin analogues relative to human insulin-response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-9.
Kazda C, Slieker L, Ilag L, Byrd R, Rees T, Prince M. Kazda C, et al. Diabetes Metab Res Rev. 2010 Mar;26(3):145-9. doi: 10.1002/dmrr.1072. Diabetes Metab Res Rev. 2010. PMID: 20474066
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ. Mudaliar S, et al. Among authors: prince mj. Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753. Diabetes Obes Metab. 2016. PMID: 27723226 Clinical Trial.
Ritonavir, triglycerides, and pancreatitis.
Perry RC, Cushing HE, Deeg MA, Prince MJ. Perry RC, et al. Among authors: prince mj. Clin Infect Dis. 1999 Jan;28(1):161-2. doi: 10.1086/517194. Clin Infect Dis. 1999. PMID: 10028103 No abstract available.
198 results